Platelet Secretome
A unique asset driving the fight
against neurodegeneration
Neurodegeneration, the leading cause of disability
worldwide affecting 80M people
A global burden and an urgent
need to promote longer, healthier lives
A Neurodegenerative disorders—whether chronic, such as Parkinson’s disease or ALS, or acute, following events like stroke or traumatic brain injury—impose an immense and growing economic burden worldwide. The combined costs of care, rehabilitation, and lost productivity already exceed hundreds of billions of dollars each year and are projected to rise sharply as populations age and survival improves. Developing effective therapies that slow disease progression or enhance recovery after injury could not only transform lives but also deliver major societal and economic benefits.
Neurodegeneration, a complex and heterogenous
degenerative process
Neurodegenerative disorders are complex and multifactorial pathologies marked by a progressive loss of neuronal function and structure. Their pathology arises from interconnected biological processes—including mitochondrial dysfunction, oxidative stress, and neuroinflammation—that together drive neuronal decline. These mechanisms do not act uniformly across individuals: their impact varies with genetic background, environmental factors, and disease stage. This biological diversity explains why the traditional «one drug–one target» paradigm has often failed to deliver effective treatments, and highlights the urgent need for innovative, multi-targeted therapeutic strategies capable of addressing the complexity of neurodegeneration.
our strategy
A biotherapy that harnesses
the platelets’ innate regenerative power
- Platelet (thrombocytes)
- Red blood cells (erythrocytes)
- White blood cells (lymphocytes)
- Primary homeostasis
- Inflammation
- Immunity
- Tissue healing & repair
- Role in mediating brain function
to promote healing and tissue repair
Platelet secretome
A novel and unique therapeutic agent, source of endless bioactive molecules promoting neuronal survival, repair and plasticity
Anti-inflammatory
SOD, GPX1, GSH, GST, Peroxiredoxin, Catalase/GPX4
Anti-oxidant Anti-ferroptotic
TGF-b, IL-4, Galectin-1, TIMP-1
Neuroprotection
PDGF, BDNF, EGF, b-FGF, VEGF, MANF, MIF
Synaptic plasticity
BDNF, PF4 (CXCL4), VEGF, Serotonin, TGF-b, Reelin
– Produced from allogenic clinical-grade platelet concentrates provided by certified blood establishments
– Pathogen free
– To targets multiple pathological mechanisms responsible for neurodegeneration
– To derisk potential toxicity to the Central Nervous System, as IVB001 is depleted of pro-neuroinflammatory factors (fibrinogen, complement…)
– To be an off-the-shelf product, compatible with chronic administration
– To be a cell-free therapy that does not have the recurring drawbacks of cellular therapies (immunogenicity, tumorigenicity, complex manufacturing…)
